Im­mat­ics and Ed­i­tas part­ner on gene edit­ing and T cells; Eye­n­ovia founder to step down from CEO po­si­tion

Two com­pa­nies deeply in­volved in gene edit­ing and T-cells are com­ing to­geth­er in a new deal.

Im­mat­ics and Ed­i­tas Med­i­cine an­nounced Tues­day that they have …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER